PMC:7200337 / 94680-96183
Annnotations
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32505227-32155444-46575426 | 175-179 | 32155444 | denotes | 2020 |
T4350 | 175-179 | 32155444 | denotes | 2020 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T736 | 297-302 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T737 | 626-634 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T738 | 803-808 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T739 | 973-981 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T740 | 1030-1038 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T98 | 803-808 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T541 | 18-26 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T542 | 69-77 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T543 | 80-89 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T544 | 662-670 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T545 | 941-949 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T546 | 1047-1055 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T547 | 1120-1128 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T548 | 1243-1251 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T549 | 1324-1332 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T550 | 1442-1451 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T974 | 295-302 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cells |
T975 | 843-845 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T976 | 939-940 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T977 | 1015-1016 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T978 | 1211-1212 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T979 | 1277-1278 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T980 | 1279-1288 | http://purl.obolibrary.org/obo/CLO_0036932 | denotes | hybridoma |
T981 | 1299-1300 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T982 | 1362-1363 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T983 | 1476-1477 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T210 | 288-294 | http://purl.obolibrary.org/obo/GO_0007613 | denotes | memory |
T211 | 626-658 | http://purl.obolibrary.org/obo/GO_0097282 | denotes | antibody-mediated neutralization |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3106 | 0-4 | Chemical | denotes | nAbs | |
3107 | 18-26 | Disease | denotes | COVID-19 | MESH:C000657245 |
3134 | 597-601 | Gene | denotes | ACE2 | Gene:59272 |
3135 | 717-721 | Gene | denotes | ACE2 | Gene:59272 |
3136 | 891-895 | Gene | denotes | ACE2 | Gene:59272 |
3137 | 1150-1154 | Gene | denotes | ACE2 | Gene:59272 |
3138 | 1425-1427 | Gene | denotes | to | Gene:6999 |
3139 | 1413-1415 | Gene | denotes | to | Gene:6999 |
3140 | 1106-1108 | Gene | denotes | to | Gene:6999 |
3141 | 840-842 | Gene | denotes | to | Gene:6999 |
3142 | 680-682 | Gene | denotes | to | Gene:6999 |
3143 | 353-355 | Gene | denotes | to | Gene:6999 |
3144 | 235-237 | Gene | denotes | to | Gene:6999 |
3145 | 36-44 | Species | denotes | Patients | Tax:9606 |
3146 | 662-672 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3147 | 825-833 | Species | denotes | patients | Tax:9606 |
3148 | 941-949 | Species | denotes | SARS-CoV | Tax:694009 |
3149 | 1047-1057 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3150 | 1120-1130 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3151 | 1243-1253 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3152 | 1324-1334 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3153 | 1416-1424 | Species | denotes | patients | Tax:9606 |
3154 | 364-375 | Species | denotes | recombinant | Tax:575864 |
3155 | 118-122 | Chemical | denotes | nAbs | |
3156 | 251-255 | Chemical | denotes | nAbs | |
3157 | 1312-1315 | Chemical | denotes | nAb | |
3158 | 69-89 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
3159 | 1442-1451 | Disease | denotes | infection | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T544 | 0-35 | Sentence | denotes | nAbs Derived from COVID-19 Patients |
T545 | 36-221 | Sentence | denotes | Patients who have recovered from SARS-CoV-2 infection are one potential source of nAbs (Chen et al., 2020a, Ju et al., 2020, Walls et al., 2020, Wölfel et al., 2020, Yuan et al., 2020). |
T546 | 222-452 | Sentence | denotes | In an effort to obtain these nAbs, scientists sorted RBD-specific memory B cells and cloned their heavy and light variable regions to express recombinant forms of the corresponding antibodies (Chen et al., 2020a, Ju et al., 2020). |
T547 | 453-614 | Sentence | denotes | Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential in vitro, and all inhibited ACE2-RBD binding. |
T548 | 615-734 | Sentence | denotes | Successful antibody-mediated neutralization of SARS-CoV-2 seemed to be dependent on the inhibition of ACE2/RBD binding. |
T549 | 735-929 | Sentence | denotes | However, Chen et al. showed that nearly all antibodies derived from serum of 26 recovered patients bound to S1 and RBD, with only three actually inhibiting ACE2/RBD binding (Chen et al., 2020a). |
T550 | 930-1167 | Sentence | denotes | Of note, a SARS-CoV-1-derived neutralizing antibody (47D11) (Wang et al., 2020a) and a single-chain antibody against SARS-CoV-2 (n3130) (Wu et al., 2020c) have also been shown to neutralize SARS-CoV-2 without inhibiting ACE2/RBD binding. |
T551 | 1168-1258 | Sentence | denotes | Thus, blocking this interaction may not be a prerequisite for an effective SARS-CoV-2 nAb. |
T552 | 1259-1503 | Sentence | denotes | The generation of a hybridoma producing a monoclonal nAb against SARS-CoV-2 provides the potential for a therapeutic Ab that can be directly administered to patients to block ongoing infection and potentially even as a prophylactic (Figure 6D). |